Cheilbio Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 03:17 am EST
Share
Cheilbio Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 3,367.34 million compared to KRW 3,858.54 million a year ago. Net loss was KRW 265.72 million compared to KRW 344.18 million a year ago. Basic loss per share from continuing operations was KRW 10 compared to KRW 14 a year ago. Basic loss per share was KRW 10 compared to KRW 14 a year ago.
For the nine months, sales was KRW 8,446.72 million compared to KRW 11,573.7 million a year ago. Net loss was KRW 852.67 million compared to KRW 1,783.37 million a year ago. Basic loss per share from continuing operations was KRW 32 compared to KRW 65 a year ago. Basic loss per share was KRW 32 compared to KRW 65 a year ago.
Cheilbio Co., Ltd. is a Korea-based company engaged in the manufacturing of veterinary drugs. The Company's offerings consist of antibiotics, antimicrobials, lactobacillus, enzyme preparations, parasiticides, antiseptics, organic trace minerals, vaccines, diagnostic kits including enzyme-linked immunosorbent assay (ELISA) test kits, virus test kits and deoxyribonucleic acid (DNA) kits, as well as feed additives. The Companyâs products are used for cattle, pigs, chickens, pets and other animals. It supplies its products mainly to the domestic market.
CHEILBIO CO., LTD. 
